Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex ...
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...
Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, ...
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
U.S.-based Vertex Pharmaceuticals (VRTX) has secured approval from the FDA (Food and Drug Administration) for its ...
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...